These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22277178)

  • 21. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracoronary infusion of levosimendan to treat postpericardiotomy heart failure.
    Caimmi PP; Grossini E; Molinari C; Vacca G; Teodori G
    Ann Thorac Surg; 2006 Nov; 82(5):e33-4. PubMed ID: 17062205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA; Marsh KC; Polakowski JS; Fryer RM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
    Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
    Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
    Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
    J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial efficiency during levosimendan infusion in congestive heart failure.
    Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function.
    Kolseth SM; Nordhaug DO; Stenseth R; Sellevold O; Kirkeby-Garstad I; Wahba A
    Eur J Cardiothorac Surg; 2009 Dec; 36(6):1024-30. PubMed ID: 19592266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance.
    Tsagalou EP; Kanakakis J; Anastasiou-Nana MI; Drakos SG; Ntalianis AS; Malliaras K; Lazaris N; Katsaros F; Nanas JN
    Acute Card Care; 2009; 11(2):99-106. PubMed ID: 19353405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of levosimendan in cardiac surgery.
    Aksun M; Karahan N; Adanir T; Aran G; Yetkin U; Oztürk T; Sencan A; Ozgürbüz U; Gürbüz A
    Anadolu Kardiyol Derg; 2009 Jun; 9(3):223-30. PubMed ID: 19520657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden.
    Thorvaldsen T; Benson L; Hagerman I; Dahlström U; Edner M; Lund LH
    Int J Cardiol; 2014 Jul; 175(1):55-61. PubMed ID: 24820737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
    Graudins A; Najafi J; Rur-SC MP
    Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
    Yontar OC; Yilmaz MB; Yalta K; Tandoğan I
    Anadolu Kardiyol Derg; 2010 Aug; 10(4):310-6. PubMed ID: 20693125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of the neutrophil to lymphocyte ratio for predicting in-hospital mortality after levosimendan infusion in patients with acute decompensated heart failure.
    Tasal A; Erturk M; Uyarel H; Karakurt H; Bacaksiz A; Vatankulu MA; Turfan M; Sonmez O; Erdogan E; Ergelen M
    J Cardiol; 2014 Jun; 63(6):418-23. PubMed ID: 24268422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.